Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Bundling Policy Should Require Full User Fee Payment – MDMA

This article was originally published in The Gray Sheet

Executive Summary

An FDA policy allowing less than full user fee payments for bundled premarket submissions would create a "disadvantage" for small manufacturers, the Medical Device Manufacturers Association states
Advertisement

Related Content

MDUFMA Guidance Clarifies Appropriate Bundling Use For Reprocessed SUDs
MDUFMA Guidance Clarifies Appropriate Bundling Use For Reprocessed SUDs
User Fees Hiked In FY ’04: Fewer Submissions, Bundling Cited As Factors
User Fees Hiked In FY ’04: Fewer Submissions, Bundling Cited As Factors
FDA Guidances Outline User Fee Collection Policy, Small Business Criteria
FDA Guidances Outline User Fee Collection Policy, Small Business Criteria
Advertisement
UsernamePublicRestriction

Register

MT018111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel